garden beds. She has trouble navigating a walker in her small mobile home. She feels that she has adequate support from her daughter and sees her daily. Working together with her home health nurse and the clinic pharmacist, a complete and accurate medication list is obtained. At a close follow‐up visit, you review each medication against the Beers list and weigh the potential benefits against probable medication burden/side effects, prioritizing drugs for discontinuation. Together with the patient and daughter, you agree on a monitoring plan to watch for any adverse events related to deprescribing.
The following medications are discontinued due to the Beers list strong recommendation to avoid use in older adults and the presence of symptoms that suggest ADR: meclizine, nifedipine, glimepiride, high‐dose aspirin (for primary prevention), and omeprazole. After evaluating for drug–drug and drug–disease interactions, it is decided to also discontinue oxybutynin (anticholinergic effects and possible interaction with donepezil), multivitamin (drug absorption interactions and limited evidence of benefit), spironolactone (drug–drug interaction with ACE inhibitor), nadolol (orthostatic hypotension and bradycardia contributing to fall), calcium (constipation and drug absorption interactions), and cilostazol (lack of indication). Dose optimization to reduce the risk of side effects and simplify the medication regimen to once‐daily dosing in the a.m. is done for the following: furosemide once daily (reduce urinary symptoms), metformin changed to ER formulation once daily, simvastatin 20 mg (reduce muscle aches), ferrous sulfate once daily (constipation), and calcium carbonate once daily (constipation). A plan for gradual dose reduction of trazodone, sertraline, and famotidine is initiated. A review of the START criteria indicates that the patient should be treated with vitamin D3 for her osteoporosis. The patient admits to not taking tramadol, so this medication is also discontinued. Non‐pharmacologic interventions of compression stockings, dietician guidance for optimal calcium and protein intake, and a therapist‐led exercise programme are initiated. A discussion is held on the risks versus benefit of statin therapy in diabetes and donepezil in probable early Alzheimer’s disease, and the decision is made to continue these with close monitoring.
Final medication list: lisinopril 5 mg daily, furosemide 20 mg daily, metformin ER 1000 mg daily, simvastatin 20 mg daily, sertraline 75 mg daily, trazodone gradually tapered off over four weeks, donepezil 10 mg daily, ferrous sulfate 325 mg daily, and vitamin D3 1000 units daily.
Her home health interprofessional team makes frequent visits over the next month. At six months, she and her daughter report that she is living independently and continuing to improve functionally, cognitively, and symptomatically with no additional falls.
In conclusion, the idea of polypharmacy as a plethora of medications should suggest something to be feared. The romantic idea of a Horn of Plenty, a beautifully overflowing cornucopia of health, does not apply to a broad medication regimen. A more concrete mythological allusion to polypharmacy is the image of the Chimera, a fire‐breathing ‘thing of immortal make, not human, lion‐fronted and snake behind, a goat in the middle’71 – a thought‐provoking combination with potential dangers. Much like polypharmacy can be conquered, the Chimera, which was once believed to be nearly invincible, was eventually defeated with a sword by Bellerophon on his winged horse, Pegasus. Appropriate prescribing combines the science of gerontology with the art of patient‐centred care, and it takes commitment and attention to assure a proper treatment balance. Medication review should be considered of utmost importance and should be done frequently and carefully, utilizing multiple members of the interprofessional team. Patients should be judiciously educated on the indications of medications as well as their correct use and dosages.
Key points
Inappropriate medication prescribing is a significant problem in geriatrics and should be evaluated in each and every medical encounter.
The presence of multiple medications in older patients is associated with higher risk for frailty, disability, mortality, and falls.
In the geriatric population, responses to medications can be very variable and not always predictable at the time of medication prescription.
An elderly patient’s protein status must be taken into account when assessing medication efficacy or toxicity.
Prescribers must always consider new symptom complaints in an older patient as a potential medication reaction, even if atypical.
Many resources and tools are available to guide appropriate medication prescribing in the older adult, and prescribers should use them regularly.
References
1 1. Wallis KA. No medicine is sometimes the best medicine. BMJ Case Rep. 2015.
2 2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365(21):2002–12.
3 3. Guthrie B, Makubate B, Hernandez‐Santiago V, Dreischulte T. The rising tide of polypharmacy and drug‐drug interactions: population database analysis 1995‐2010. BMC Med. 2015; 13:74.
4 4. Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug‐drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther. 2007; 45(12):643–53.
5 5. Franchi C, Tettamanti M, Pasina L, et al. Changes in drug prescribing to Italian community‐dwelling elderly people: the EPIFARM‐Elderly Project 2000–2010. Eur J Clin Pharmacol. 2014; 70(4):437–43.
6 6. Gillette C, Prunty L, Wolcott J, Broedel‐Zaugg K. A new lexicon for polypharmacy: Implications for research, practice, and education. Res Social Adm Pharm. 2015; 11(3):468–71.
7 7. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13(1):57–65.
8 8. Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013; 30(5):285–307.
9 9. United States. Congress. Senate. Committee on Finance. Omnibus Budget Reconciliation Act of 1987: explanation of provisions approved by the committee on December 3, 1987 for inclusion in Leadership Deficit Reduction Amendment. Washington: US GPO; 1987:vi.
10 10. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community‐dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012; 65(9):989–95.
11 11. Steinman MA, Miao Y, Boscardin WJ, Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014; 29(10):1379–86.
12 12. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11‐year national analysis. Pharmacoepidemiol Drug Saf. 2010; 19(9):901–10.
13 13. Mannucci PM, Nobili A, Pasina L, Collaborators R. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med. 2018; 13(8):1191–200.
14 14. Doan J, Zakrzewski‐Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450‐mediated drug‐drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013; 47(3):324–32.
15 15. Cepeda OA MJ. Polypharmacy, is it another disease? In: Pathy MS SA, Morley JE, eds. Principles and Practice of Geriatric Medicine. 4th ed. John Wiley & Sons, Ltd; 2006:215–21.
16 16. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med. 2002; 18(3):577–92.
17 17. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross‐sectional and longitudinal study. J Gerontol. 1976; 31(2):155–63.
18 18. David SP. Pharmacogenetics. Prim Care. 2004; 31(3):543–59, ix.
19 19. Brockmoller J, Stingl JC. Multimorbidity, polypharmacy and pharmacogenomics in old age. Pharmacogenomics.